This Oct 18, 2021 handout photo courtesy of Merck & Co,Inc. shows capsules of the antiviral pill Molnupiravir. (HANDOUT / MERCK & CO,INC. / AFP)
WASHINGTON / HAVANA / LONDON / PARIS – President Joe Biden's administration is aiming to expand access to COVID-19 oral antiviral treatments like Pfizer Inc's Paxlovid by doubling the number of locations at which they are available, the White House said on Tuesday.
The administration expects to increase their direct distribution to over 30,000 locations soon and reach 40,000 sites over the coming weeks, the official said
Pharmacies participating in the federal pharmacy program for distributing antiviral treatments will be able to order the free treatments directly from the US government starting this week.
Currently, the pharmacies were dependent on states to obtain the pills. The government sends the treatments to select pharmacies, as well as directly to states and community centers. Under the current system, the treatments are available in around 20,000 locations.
"There's more room to save more lives by getting this medication to more people," a senior administration official told reporters on a press call.
ALSO READ: Africa's COVID-19 cases near 11.41m
The administration expects to increase their direct distribution to over 30,000 locations soon and reach 40,000 sites over the coming weeks, the official said.
Demand for Paxlovid has been unexpectedly light due to complicated eligibility requirements, reduced testing, and potential for drug interactions.
Paxlovid was expected to be a major tool in the fight against COVID-19 after it reduced hospitalizations or deaths in high-risk patients by around 90 percent in a clinical trial.
There are only a few proven antiviral treatments. The others are Merck & Co's far less effective rival pill molnupiravir, and Gilead Sciences Inc's intravenous remdesivir.
The United States has agreed to buy up to 20 million pills at around $530 a course and Pfizer is on pace to produce 3.5 million courses earmarked for US use by the end of April.
Through the first half of April, US data shows it has distributed around 1.5 million courses and that pharmacies still have over 500,000 available.
ALSO READ: COVID-19 was third leading death cause in US in 2021
The government also plans to roll out more federally supported test sites as part of its "Test to Treat" initiative that allows Americans to get tested for COVID-19 at a pharmacy and receive free pills if they test positive.
There are currently 2,200 such sites and the White House expects an additional 10,000 to come online right away.
The administration also aims to boost patient and provider awareness through public education campaigns.
Cuba
Cuba on Monday recorded 237 COVID-19 infections with no death in the last day, the lowest daily count of the year, bringing national tally to 1,101,968 with 8,525 deaths, the Ministry of Public Health said.
Cuba on Monday recorded 237 COVID-19 infections with no death in the last day, the lowest daily count of the year, bringing national tally to 1,101,968 with 8,525 deaths, the Ministry of Public Health said
So far, 9.9 million of Cuba's 11.2 million residents have been fully vaccinated against the virus, while 6.5 million have received a booster dose.
The national vaccination campaign is being carried out with three Cuban-made vaccines, namely Abdala, Soberana-02 and Soberana Plus.
Valneva
French drugmaker Valneva said on Monday that the European Medicines Agency had asked for more data on its COVID-19 vaccine, precipitating a sharp fall in its shares.
The latest EMA setback comes after Britain earlier this month cleared the use of Valneva's vaccine, becoming the first European country to give its shot the green light. read more
Valneva said the EMA Committee for Medicinal Products for Human Use had a fresh list of questions, including requests for additional data and for further justification of a conditional marketing authorisation for the vaccine.
